This is a revised version of this press
release, originally issued Jan. 27, 2006.
The release was revised to clarify recommendations for baseline tests.
FDA News
|
FOR IMMEDIATE RELEASE
P06-13
January 27, 2006
|
Media
Inquiries:
Laura Alvey,
301-827-6242
Consumer Inquiries:
888-INFO-FDA |
There is a new, potential alternative for many of the more than 5 million
Americans who take insulin injections, with the Food and Drug Administration's
approval today of the first ever inhaled insulin. Exubera, an inhaled powder
form of recombinant human insulin (rDNA) for the treatment of adult patients
with type 1 and type 2 diabetes, is the first new insulin delivery option introduced
since the discovery of insulin in the 1920s.
"Until today, patients with diabetes who need insulin to manage their
disease had only one way to treat their condition," said Dr. Steven Galson,
Director, Center for Drug Evaluation and Research, FDA. "It is our hope
that the availability of inhaled insulin will offer patients more options to
better control their blood sugars."
Diabetes is a disease that affects the amount of insulin and sugar in your
body. Exubera is a human form of insulin and as such, lowers blood sugar concentrations
by allowing the blood sugar to be taken up by cells as a source of fuel. Exubera
is a powdered form of insulin that is able to be inhaled into the lungs through
the patient's mouth using a specially designed inhaler.
There are two major types of diabetes -- type 1 and type 2. People with
type 1 diabetes produce virtually no insulin. In type 2, the most common form
of the disease, the body does not produce enough insulin or effectively use
insulin. If people with diabetes do not properly control their blood sugar
levels, serious complications including heart disease, kidney failure, blindness,
and nerve damage may develop.
The safety and efficacy of Exubera have been studied in approximately 2500
adult patients with type 1 and type 2 diabetes. In clinical studies, Exubera
reached peak insulin concentration more quickly than some insulins, called
regular insulin, administered by an injection. Peak insulin levels were achieved
at 49 minutes (range 30 to 90 minutes) with Exubera inhaled insulin compared
to 105 minutes (range 60 to 240 minutes) with regular insulin, respectively.
In type 1 diabetes, inhaled insulin may be added to longer acting insulins
as a replacement for short-acting insulin taken with meals. In type 2 diabetes,
inhaled insulin may be used alone, along with oral (non-insulin) pills that
control blood sugar, or with longer acting insulins.
Exubera prescriptions will be accompanied by a Medication Guide containing
FDA-approved information written especially for patients. Pharmacists are required
to distribute Medication Guides with products FDA has determined are important
to health, and patient adherence to directions for use is crucial to the product's
effectiveness. Patients are advised to read the entire Medication Guide and
talk to their healthcare provider if they have further questions.
Like any insulin product, low blood sugar is a side effect of Exubera and
patients should carefully monitor their blood sugars regularly. Other side
effects associated with Exubera therapy seen in clinical trials included cough,
shortness of breath, sore throat, and dry mouth.
Exubera is not to be used if you smoke or if you recently quit smoking (within
the last 6 months). Exubera is not recommended in patients with asthma, bronchitis,
or emphysema. Baseline tests for lung function are recommended after the first
6 months of treatment and every year thereafter, even if there are no pulmonary
symptoms.
While Exubera has been extensively studied for safety, the sponsor has committed
to performing long-term studies to confirm the continued safety of Exubera
after it is marketed and to examine more thoroughly the issue of the efficacy
and safety of Exubera in patients with underlying lung disease.
Exubera is manufactured by Pfizer Inc., NY, NY.
####
From the FDA
January 27, 2006
http://www.fda.gov/bbs/topics/news/2006/NEW01304.html
|
|
|